Patents Assigned to NEOGENOMICS LABORATORIES, INC.
  • Deep sequecing of peripheral blood plasma DNA as a reliable test for confirming the diagnosis of myelodysplastic syndrome
    Patent number: 10604801
    Abstract: Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: March 31, 2020
    Assignee: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher Albitar
  • Determining tumor load and biallelic mutation in patients with CALR mutation using peripheral blood plasma
    Patent number: 10550435
    Abstract: Compositions and fragment length analysis methods are provided for detecting CALR mutations and determining tumor load in patients with myeloproliferative neoplasms.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: February 4, 2020
    Assignee: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher Albitar
  • Method to increase sensitivity of detection of low-occurrence mutations
    Patent number: 10329605
    Abstract: A method for detecting a low-occurrence mutation in isolated DNA adds a blocking probe to reagents during amplification of the isolated DNA. The blocking probe is an oligonucleotide complementary to wild-type DNA corresponding to the sample. The blocking probe spans a site of a suspected mutation within a region of interest in the isolated DNA. After amplification, fragments of the amplified DNA is sequenced using next generating sequencing and an output is generated to display the sequenced fragments. In some embodiments, the blocking probe is locked nucleic acid (LNA).
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: June 25, 2019
    Assignee: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher Albitar
  • High-sensitivity sequencing to detect BTK inhibitor resistance
    Patent number: 10253370
    Abstract: A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: April 9, 2019
    Assignee: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher Albitar
  • Method for high sensitivity detection of MYD88 mutations
    Patent number: 10227657
    Abstract: A method for increasing sensitivity for detecting minority mutations in MYD88 uses a locked nucleic acid oligo to block amplification of wild-type DNA in DNA isolated from patient FFPE tissue, bone marrow aspirate or peripheral blood samples during PCR while still allowing sequencing and visualization of the PCR product. Further improvement to the sensitivity may be achieved by using a uracil DNA-glycosylase treatment to remove sequence artifacts commonly found in formalin-fixed, paraffin-embedded tissue.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: March 12, 2019
    Assignee: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher Albitar
  • COMPOSITIONS AND METHODS FOR DETECTING AND DETERMINING A PROGNOSIS FOR PROSTATE CANCER
    Publication number: 20140336280
    Abstract: The present disclosure provides methods of detecting and determining the aggressiveness of prostate cancer. These methods can be used to determine whether or not a patient needs a biopsy as well as guide treatment selection.
    Type: Application
    Filed: March 13, 2014
    Publication date: November 13, 2014
    Applicant: NEOGENOMICS LABORATORIES, INC.
    Inventor: Maher ALBITAR